Drug intelligence / Profile preview

GST-HG191

Development stage: Preclinical
Lead developer: Fujian Akeylink Biotechnology

Overview

GST-HG191 is an investigational drug candidate currently in the preclinical or IND-enabling stage of development by Fujian Akeylink Biotechnology. As of the latest company pipeline updates, the specific therapeutic indication, molecular target, and modality for GST-HG191 have not been publicly disclosed. It represents one of the earlier-stage assets in Akeylink's portfolio, which also includes treatments for COVID-19, chronic hepatitis B, and solid tumors.

Beyond the preview

Go deeper on GST-HG191.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GST-HG191.

Explore the full profile